|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||45.55|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Bellicum Pharmaceuticals (BLCM) was a big mover last session, as the company saw its shares rise nearly 14% on the day.
IPSEN (IPSEY) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Categories: Yahoo FinanceGet free summary analysis Ipsen SA reports financial results for the half-year ended June 30, 2017. Highlights Summary numbers: Revenues of USD 1,006.37 million, Net Earnings of USD 136.04 million. Gross margins widened from 77.45% to 79.31% compared to the same period last year, operating (EBITDA) margins now 25.71% from 18.16%. Change in operating cash ... Read more (Read more...)
Commercial Vehicle Group, MTS Systems, Ipsen, AXA and Arkema highlighted as Zacks Bull and Bear of the Day
The CAC 40 index achieved its highest close since Aug 2015 as investors welcomed the prospect of Macron becoming France's next president.
Categories: Yahoo Finance Get free summary analysis Ipsen SA reports financial results for the half-year ended December 31, 2016. Highlights Summary numbers: Revenues of USD 898.44 million, Net Earnings of USD 101.25 million. Gross margins widened from 76.92% to 77.94% compared to the same period last year, operating (EBITDA) margins now 18.93% from 17.25%. Change in operating cash ... Read more (Read more...)
The U.S. Food and Drug Administration said on Tuesday it had approved Lexicon Pharmaceuticals Inc's oral drug to treat carcinoid syndrome diarrhea, a condition that develops in patients with gastrointestinal tumors. The drug, Xermelo or telotristat ethyl, was tested on patients unable to tolerate somatostatin analog therapy (SSA) — the standard-of-care treatment for carcinoid syndrome diarrhea from companies such as Novartis AG and Ipsen SA .
Categories: Yahoo Finance Get free summary analysis Ipsen SA reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Ipsen SA – Sanofi Sponsored ADR and Catalent Inc (SNY-US and CTLT-US) that have also reported for this period. Highlights Gross margins widened from 76.66% to 77.70% compared to ... Read more (Read more...)
Drugmaker Sanofi is close to selling some over-the-counter products to Ipsen SA, in a deal that could be valued at nearly 100 million euros , Bloomberg reported. The deal between the French drugmakers ...
The Nasdaq-listed cancer drug developer is up 43% in premarket trading after promising shareholders special dividends worth more than its closing share price on Friday.
The deal would give Merrimack the resources to fund the development of three new compounds targeting pancreatic, lung, and other types of cancers. It would boost Ipsen's portfolio, which has traditionally focused on endocrinology. Ipsen will pay $575 million at the closing of the deal and up to $450 million more, contingent on some approvals for Onivyde in the United States.
Categories: Yahoo Finance Ipsen SA relative valuation is now NEUTRAL. It was previously rated OVERVALUED, and has a fundamental analysis score of 84. Our analysis is based on comparing Ipsen SA with the following peers – Sanofi Sponsored ADR, Innoviva, Inc., Catalent Inc and Revance Therapeutics, Inc. (SNY-US, INVA-US, CTLT-US and RVNC-US). Relative Valuation Ipsen SA is currently ... Read more (Read more...)